<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03146013</url>
  </required_header>
  <id_info>
    <org_study_id>MP EIA-HTLV-001B Amendment 6.0</org_study_id>
    <nct_id>NCT03146013</nct_id>
  </id_info>
  <brief_title>Dual Algorithm Post Market Clinical Study</brief_title>
  <official_title>Evaluation of the MP Diagnostics HTLV Blot 2.4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MP Biomedicals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MP Biomedicals Asia Pacific Pte. Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MP Biomedicals, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the validity and reproducibility of the MP Diagnostics
      HTLV Blot 2.4 in blood specimens testing repeat reactive (RR) on the first FDA licensed
      screening assay (Abbott Prism) and non-reactive (NR) on the second FDA licensed screening
      assay (Avioq ELISA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study designed to assess the safety and effectiveness of a dual
      algorithm testing for HTLV I/II in blood donors. The study hypothesis is that blood donors
      testing repeat reactive (RR) on the first FDA licensed HTLV screening assay and non-reactive
      (NR) on a second FDA licensed screening assay will be confirmed as indeterminate or negative
      on the MP Diagnostics HTLV Blot 2.4.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">May 31, 2017</completion_date>
  <primary_completion_date type="Actual">May 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the HTLV dual algorithm testing in blood donor facilities</measure>
    <time_frame>3 months</time_frame>
    <description>HTLV I/II confirmation of specimens testing RR on the first FDA licensed HTLV screening assay and non-reactive (NR) on a second FDA licensed HTLV screening assay.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>HTLV-I Infections</condition>
  <condition>HTLV-II Infections</condition>
  <condition>Human T-lymphotropic Virus 1</condition>
  <condition>Human T-lymphotropic Virus 2</condition>
  <condition>HTLV I Associated T Cell Leukemia Lymphoma</condition>
  <condition>HTLV I Associated Myelopathies</condition>
  <arm_group>
    <arm_group_label>HTLV Repeat Reactive (RR) / Non Reactive (NR)</arm_group_label>
    <description>Blood donor specimens that tested repeat reactive on the first FDA licensed HTLV screening assay and non-reactive on the second FDA licensed HTLV screening assay</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MP Diagnostics HTLV Blot 2.4</intervention_name>
    <description>HTLV I/II Confirmation and Differentiation</description>
    <arm_group_label>HTLV Repeat Reactive (RR) / Non Reactive (NR)</arm_group_label>
    <other_name>HTLV I/II Western Blot Assay</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All populations are from whole blood donors.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female

          2. Completion of a health history evaluation for routine donor screening

          3. Provided a routine blood donation

          4. Tests repeat reactive by the Abbott PRISM HTLV assay and non-reactive on the AVIOQ
             Elisa HTLV assay

        Exclusion Criteria:

          1. Unwilling or unable to provide informed consent to blood donation

          2. Inadequate sample volume for testing

          3. Unable to provide samples that meet the suitability requirements for testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Stramer, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>American National Red Cross</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>American Red Cross - National Testing Laboratory</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28273</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Miller L. Profile of the MP Diagnostics HTLV Blot 2.4 test: a supplemental assay for the confirmation and differentiation of antibodies to HTLV-1 and HTLV-2. Expert Rev Mol Diagn. 2016;16(2):135-45. doi: 10.1586/14737159.2016.1123622. Epub 2016 Jan 11. Review.</citation>
    <PMID>26589659</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HTLV</keyword>
  <keyword>Confirmatory</keyword>
  <keyword>Supplemental</keyword>
  <keyword>Blot</keyword>
  <keyword>HTLV-I</keyword>
  <keyword>HTLV-II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Spinal Cord Diseases</mesh_term>
    <mesh_term>Paraparesis, Tropical Spastic</mesh_term>
    <mesh_term>HTLV-I Infections</mesh_term>
    <mesh_term>HTLV-II Infections</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual patient data (IPD) was deidentified prior to sharing.</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>March 21, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

